Vumerity (diroximel fumarate; Biogen) has been approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
More than half of patients with multiple sclerosis experienced a wearing-off effect during treatment with natalizumab.
With an improved specificity, an updated algorithm for the detection of UTIs in patients with relapsing MS addresses previous issues concerning the unnecessary prescription of antibiotics, whilst improving accuracy and maintaining safety.
Further understanding of the recently recognized symptomatic, measurable prodrome phase in multiple sclerosis will increase clinicians’ ability to diagnose and manage the disease earlier.
A high percentage of neurologists report diagnosing secondary progressive multiple sclerosis over a shorter period than that suggested by clinical guidance, and a greater number of neurologists who focus on multiple sclerosis diagnose and treat patients with SPMS than general neurologists.
Among women with active relapsing-remitting multiple sclerosis, continuation of natalizumab treatment until the end of the first trimester is associated with significantly reduced disease reactivation compared with stopping natalizumab at conception.
Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis) resulted in a highly significant and clinically meaningful reduction in the number of confirmed relapses, compared with teriflunomide, a pyrimidine synthesis inhibitor, in patients with relapsing forms of multiple sclerosis.
AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
Patients with MS and comorbid seizures or epilepsy presenting to a neurology department in at one hospital in Germany between 2003 and 2015 were identified.
Dimethyl fumarate induced changes in the multiple sclerosis lymphocyte repertoire, indicating that lymphocyte subset monitoring is not required for safety vigilance.
Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
The clinician workgroup achieved a consensus and report a 3-step iterative management algorithm for MS relapses.
Researchers have developed a diagnostic protocol for identifying INO in Patients With MS.
EMD Serono announced that the Food and Drug Administration (FDA) has approved Mavenclad (cladribine) tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS).
The FDA has approved siponimod for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.